Vizenpistat is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2'3'-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer[1][2].
Molecular Weight:
367.42
Purity:
98.88
CAS Number:
[2687222-58-6]
Formula:
C15H21N5O4S
Target:
Phosphodiesterase (PDE),STING
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
